Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination-Reference-Cited by-同舟云学术

Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Papp-Wallace Krisztina M.¹²³⁴,Bethel Christopher R.¹,Caillon Jocelyne⁵⁶^ORCID,Barnes Melissa D.¹²,Potel Gilles⁵⁶,Bajaksouzian Saralee²⁷,Rutter Joseph D.¹,Reghal Amokrane⁶,Shapiro Stuart⁸,Taracila Magdalena A.¹²,Jacobs Michael R.²⁷,Bonomo Robert A.¹⁹¹⁰²³,Jacqueline Cédric⁵⁶

Affiliation:

1. Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA

2. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

3. Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

4. Department of Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

5. EA 3826 (Thérapeutiques Anti-Infectieuses), IRS2 Nantes Biotech, Université de Nantes, France

6. Atlangram, IRS2 Nantes Biotech, Nantes, France

7. Department of Pathology, University Hospitals, Cleveland Medical Center, Cleveland, Ohio, USA

8. Allecra Therapeutics SAS, Saint-Louis, France

9. Medical Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA

10. Geriatric Research Education and Clinical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA

Abstract

Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and disseminate around the world.

Funder

HHS | National Institutes of Health

U.S. Department of Veterans Affairs

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00105-19

Reference43 articles.

1. O’Neill J (chair). 2014. Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Her Majesty’s Government and Wellcome Trust. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.

2. Characterization of a New Metallo-β-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India

3. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study

4. World Health Organization. 2015. Global action plan on antimicrobial resistance. WHO Geneva Switzerland. https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/.

5. The ABCD’s of β-lactamase nomenclature

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis;Journal of Global Antimicrobial Resistance;2024-12

2. Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates;Journal of Global Antimicrobial Resistance;2024-09

3. Gramnegative Erreger (3MRGN/4MRGN): Häufigkeit und Besonderheiten;DMW - Deutsche Medizinische Wochenschrift;2024-09

4. New Agents Are Coming, and So Is the Resistance;Antibiotics;2024-07-13

5. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07